Simulations Plus Stock
StockStockPrice
Historical dividends and forecast
Simulations Plus has so far distributed $0.18 in 2024. The next dividend will be paid on 05.02.2025
CHART BY
Frequently asked questions
What is Simulations Plus's market capitalization?
What is Simulations Plus's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Simulations Plus?
What are the analyst ratings and target price for Simulations Plus's stock?
What is Simulations Plus's revenue over the trailing twelve months?
What is the EBITDA for Simulations Plus?
What is the free cash flow of Simulations Plus?
What is the 5-year beta of Simulations Plus's stock?
How many employees does Simulations Plus have, and what sector and industry does it belong to?
What is the free float of Simulations Plus's shares?
Financials
Market Cap
$645.16M5Y beta
0.76EPS (TTM)
$0.489Free Float
16.43MP/E ratio (TTM)
65.69Revenue (TTM)
$70.01MEBITDA (TTM)
$11.80MFree Cashflow (TTM)
$4.22MPricing
Analyst Ratings
The price target is $60.33 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The Company’s comprehensive bio simulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. It operates through two segments: software and services. It offers software products for pharmaceutical research, development, and commercialization, including GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym and others. In addition, it also delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development.
243
Software & Programming
Health Care
Identifier
ISIN
Primary Ticker